WHAT IS SPRAVATO?

SPRAVATO® (esketamine) CIII nasal spray is a nonselective, noncompetitive antagonist of the N-methyl-D-aspartate
(NMDA) receptor – an ionotropic glutamate receptor.

It is a first-of-its kind medicine approved by the FDA in two major
depressive disorder (MDD) subpopulations with high unmet need.1

SPRAVATO® is approved in the United States, in conjunction with an oral antidepressant, to treat adults with treatment resistant
depression (TRD) and to treat depressive symptoms in adults with MDD with acute suicidal ideation or
behavior.

SPRAVATO (ESKETAMINE)

Spravato is administered through a nasal spray, which is used in conjunction with an antidepressant medication to treat depression in adults who have not responded to other treatments. Spravato is FDA approved for use in TRD, which is a more severe form of depression that does not respond to multiple medications.

It is important to note that Spravato can have significant side effects, including sedation, dissociation, and an increased risk of abuse and dependence. As such, it is only available through a restricted distribution program and must be administered in a healthcare setting under the supervision of a healthcare provider.

If you are experiencing symptoms of depression or have taken two or more antidepressants and still experience symptoms of depression, you can ask your healthcare provider at KND Behavioral Health Clinic, if Spravato is right for you.

KND BEHAVIORAL HEALTH CLINIC, PLLC

WHAT IS SPRAVATO?

SPRAVATO (ESKETAMINE)

Spravato is covered by most major insurance payers.

Contact us to learn more!